Plain-English translation of NCT06839053 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new medication, works better when combined with other cancer drugs (either or ) for blood cancers that affect lymph cells. The study will gradually increase the dose of the new medication to find the safest and most effective level. Researchers want to see if this combination can help patients whose cancer has come back or stopped responding to previous treatments.
Some patients with these blood cancers stop responding to existing treatments, and their cancer returns or progresses. This trial is exploring whether adding this medication to standard treatments might help patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
Depending on your specific condition and prior treatment history, you will take the new medication by mouth daily, starting at a low dose and gradually increasing it over several weeks. You will also take one of two standard cancer drugs (either or ) by mouth. Treatment cycles last 28 days and continue for up to 15 cycles, unless your disease progresses or side effects become too severe. You will have regular CT scans, blood tests, and possibly bone marrow biopsies to monitor your response, plus follow-up visits for up to 5 years after treatment ends.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States